Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin in COVID-19 ARDS
NCT04482712Phase 2Withdrawn
- Sponsor
- UT Health San Antonio
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by UT Health San Antonio. Planned start Apr 2021; status: withdrawn.
02
Drugs
sirolimus
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04482712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482712.